OBJECTIVE To describe detailed MRI results from 2 head-to-head phase III trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis Study I (CARE-MS I; NCT00530348) and Study II (CARE-MS II; NCT00548405), of alemtuzumab vs subcutaneous interferon β-1a (SC IFN-β-1a) in patients with active relapsing-remitting multiple sclerosis (RRMS). METHODS The impact of alemtuzumab 12 mg vs...

OBJECTIVE To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS In the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II study (NCT00548405), alemtuzumab-treated patients received 2 courses (baseline and 12 months later). Patients could enter an...

Objectives—The eVect of interferon-â1a (INF-â1a; Rebif) was studied in patients with chronic motor neuropathies not improving after conventional treatments such as immunoglobulins, steroids, cyclophosphamide or plasma exchange. Methods—A prospective open study was performed with a duration of 6–12 months. Three patients with a multifocal motor neuropathy and one patient with a pure motor form o...

OBJECTIVE To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. METHODS The regulatory submissions of the CLAD Tablets Treating Multiple Sclerosis Orally (CLARITY) (NCT00213135) cladribine and Comparison of Alemtuzumab and Rebif Effic...

BACKGROUND Within the past 10 years, several immunomodulatory agents (IMAs) have become available for the treatment of relapsing multiple sclerosis (MS), making therapeutic decisions more complex. We performed a systematic review of the literature to assess the efficacy and safety of these agents on physical, inflammatory, and cognitive measures of disease activity. METHODS We identified rele...

OBJECTIVE To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. METHODS Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compar...

we aimed to compare the therapeutic effect of avonex (av), betaferon (be) & rebif (re) on the expanded disability status scale (edss) in multiple sclerosis (ms). ninety patients referring to farshchian hospital were entered in this study. the patients were divided into three equal groups: group 1 received av, group 2 received re and group 3 received be, and after 24 months, comparison was done ...

background: this study was performed to compare the effects of low dose interferon beta-1 (ifn-β-1) (cinnovex, 30 mcg) and high dose ifn-β-1 (rebif, 44 mcg) on the reduction of the number and size of plaques in magnetic resonance imaging (mri) in patients with multiple sclerosis (ms). methods: this historical cohort study, which was performed in 2014 in sanandaj (western part of iran). 43 ms pa...

background: multiple sclerosis (ms) is the most common demyelinating and inflammatory disease of the central nevus system especially in young adults, but in a subgroup of patients the first clinical symptoms present after the age of 50. this clinical presentation is defined as late-onset multiple sclerosis (loms). the incidence and prevalence of ms including loms vary geographically. the aim of...

AIM Subcutaneous (s.c.) peginterferon beta-1a injected once every 2 weeks and s.c. interferon beta-1a injected three times per week (Rebif®) have demonstrated efficacy in relapsing-remitting multiple sclerosis, but direct comparisons of pharmacological activity and tolerability between the two products are lacking. COMPARE was an open label, crossover, pharmacokinetic (PK) study evaluating drug...